Tag Archive | "Kyowa Hakko Kirin"

Biovail to pay Kyowa Hakko Kirin up to $65 million for US and Canadian rights to Parkinson’s drug

Tags: ,

BLS has paid an upfront fee of $10 million, and could pay up to $20 million in potential development milestones through U.S. Food and Drug Administration (FDA) approval and up to an additional $35 million if certain sales-based milestones are met. Read the full story

Dicerna in deal with Kyowa Hakko Kirin to develop RNAi cancer treatments

Tags: ,

Dicerna will receive $4 million in upfront cash payments including research funding, and up to $120 million in additional research funding, development and commercial milestones for exclusive rights to one target in the field of oncology. Read the full story